Uvantis Therapeutics, Inc.
New Form D on file · 2026-09-23 · the record
What the record says
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $100K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
William Sheahan is named as Director on the Form D that Uvantis Therapeutics, Inc. filed with the SEC on 23 September 2026, one of 5 people that filing names.
Jonathan Young is named as Director on the Form D that Uvantis Therapeutics, Inc. filed with the SEC on 23 September 2026, one of 5 people that filing names.
Edward Woo is named as Director on the Form D that Uvantis Therapeutics, Inc. filed with the SEC on 23 September 2026, one of 5 people that filing names.
Paul Giannasca is named as Executive Officer on the Form D that Uvantis Therapeutics, Inc. filed with the SEC on 23 September 2026, one of 5 people that filing names.
Jeffrey Collins is named as Executive Officer on the Form D that Uvantis Therapeutics, Inc. filed with the SEC on 23 September 2026, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2026-09-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 5 people named on the filing — 2 holding an executive role and 3 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Uvantis Therapeutics, Inc.
- Source Check — verify Omkar Mahajan's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Omkar Mahajan for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Uvantis Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Uvantis Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.